Evidence map›Paper›PMID 42154348›Full record

ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2026

Neuroimmunomodulation of AMPA Receptors Through Combination of Medium-Chain Triglycerides and Perampanel to Treat Status Epilepticus in Anti-NMDA Receptor Encephalitis.

Laura Marie Stadler, Laurin Schappe, Piergiorgio Lochner, Luna Bonifer, Mathias Fousse, Sven G Meuth, Sergiu Groppa, Yaroslav Winter

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Laura Marie StadlerDepartment of Neurology, Saarland University Medical Center, University of Saarland, Kirrberger Str. 100, Homburg, D-66421, Germany.
Laurin SchappeDepartment of Neurology, Saarland University Medical Center, University of Saarland, Kirrberger Str. 100, Homburg, D-66421, Germany.
Piergiorgio LochnerDepartment of Neurology, Saarland University Medical Center, University of Saarland, Kirrberger Str. 100, Homburg, D-66421, Germany.
Luna BoniferDepartment of Neurology, Saarland University Medical Center, University of Saarland, Kirrberger Str. 100, Homburg, D-66421, Germany.
Mathias FousseDepartment of Neurology, Saarland University Medical Center, University of Saarland, Kirrberger Str. 100, Homburg, D-66421, Germany.
Sven G MeuthDepartment of Neurology, University Hospital Münster, Münster, Germany.
Sergiu GroppaDepartment of Neurology, Saarland University Medical Center, University of Saarland, Kirrberger Str. 100, Homburg, D-66421, Germany.
Yaroslav WinterDepartment of Neurology, Saarland University Medical Center, University of Saarland, Kirrberger Str. 100, Homburg, D-66421, Germany. yaroslav.winter@uks.eu.ORCID http://orcid.org/0000-0001-9854-4038

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies have shown that a ketogenic diet containing medium-chain triglycerides (MCTs) has a synergistic effect with perampanel in modulating AMPA receptors. Both MCTs and perampanel have immunomodulatory properties. However, the use of the combination of MCTs and perampanel to treat status epilepticus caused by autoimmune encephalitis has never been investigated. After multiple antiseizure (benzodiazepines, levetiracetam, brivaracetam, lacosamide, ketamine, propofol, and isoflurane) and immunomodulatory treatments (glucocorticoid pulse (days 4-8), intravenous immunoglobulin (days 10-12), plasmapheresis (days 13-19), rituximab (days 22 and 34), cyclophosphamide (day 38)), failed to interrupt status epilepticus in a 33-year-old woman caused by paraneoplastic anti-N-methyl-D-aspartate (NMDA) receptor encephalitis, we initiated perampanel treatment (12 mg/day), which significantly reduced ictal activity in the EEG. Status epilepticus was finally terminated when MCTs were added to the perampanel treatment regimen. Our clinical data may support previous in vitro studies demonstrating that combining perampanel with MCTs improves the neuroimmunomodulatory effect on AMPA receptors. MCTs may have a synergistic effect when added to perampanel to treat autoimmune status epilepticus. The possible cumulative effects of combination with other immune therapies in our case cannot be completely excluded.

Indexed as

AnticonvulsantsEncephalitisPyridonesReceptors, AMPAStatus EpilepticusTriglyceridesAdultDrug Therapy, CombinationFemaleHumansNitrilesAnticonvulsantsNitrilesperampanelPyridonesReceptors, AMPATriglyceridesAnti-NMDA receptor encephalitisAutoimmune encephalitisMedium-chain triglyceridesPerampanelStatus epilepticus

Identifiers

PMID42154348
PMCPMC13186854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.